You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Ketamine metabolite. Enhances AMPA receptor-mediated excitatory post-synaptic potentials in the CA1 region of hippocampal slices. Decreases intracellular D-serine (a NMDA co-agonist) concentrations in PC-12 cells (IC50 = 0.68 nM). Exerts antidepressant effects in mice. Lacks ketamine-related side effects.
Sold under license from the NIH, US patent 62/313,309
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 276.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.62 mL||18.11 mL||36.21 mL|
|5 mM||0.72 mL||3.62 mL||7.24 mL|
|10 mM||0.36 mL||1.81 mL||3.62 mL|
|50 mM||0.07 mL||0.36 mL||0.72 mL|
References are publications that support the biological activity of the product.
Singh et al (2016) KA metabolites enantioselectively decrease intracellular D-serine concentrations in PC-12 cells. PLoS One 11 e0149499 PMID: 27096720
Zanos et al (2016) NMDAR inhibition-independent antidepressant actions of KA metabolites. Nature 533 481 PMID: 27144355
If you know of a relevant reference for 2R,6R-Hydroxynorketamine hydrochloride, please let us know.
View Related Products by Target
Keywords: 2R,6R-Hydroxynorketamine hydrochloride, 2R,6R-Hydroxynorketamine hydrochloride supplier, Potent, AMPA, agonists, agonism, ketamine, metabolites, antidepressants, enantiomer, APJ, 2R,6R-HNK, Receptors, Ketamine, and, Metabolites, 6094, Tocris Bioscience
3 Citations for 2R,6R-Hydroxynorketamine hydrochloride
Citations are publications that use Tocris products. Selected citations for 2R,6R-Hydroxynorketamine hydrochloride include:
Chou et al (2018) (2R,6R)-hydroxynorKA rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray. Neuropharmacology 139 1 PMID: 29953886
Ye et al (2019) KA metabolite (2R,6R)-hydroxynorKA enhances aggression via periaqueductal gray glutamatergic transmission. Neuropharmacology 157 PMID: 31207251
Ago et al (2019) (R)-Ketamine induces a greater increase in prefrontal 5-HT release than (S)-Ketamine and Ketamine Metabolites via an AMPA receptor-independent mechanism. Int J Neuropsychopharmacol 22 665 PMID: 31325908
Do you know of a great paper that uses 2R,6R-Hydroxynorketamine hydrochloride from Tocris? Please let us know.
Reviews for 2R,6R-Hydroxynorketamine hydrochloride
There are currently no reviews for this product. Be the first to review 2R,6R-Hydroxynorketamine hydrochloride and earn rewards!
Have you used 2R,6R-Hydroxynorketamine hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.